Systemic lupus erythematosus pathophysiology: Difference between revisions

Jump to navigation Jump to search
Mmir (talk | contribs)
Mmir (talk | contribs)
Line 120: Line 120:
!HLA class2<ref name="pmid12867584">{{cite journal |vauthors=Lee HS, Chung YH, Kim TG, Kim TH, Jun JB, Jung S, Bae SC, Yoo DH |title=Independent association of HLA-DR and FCgamma receptor polymorphisms in Korean patients with systemic lupus erythematosus |journal=Rheumatology (Oxford) |volume=42 |issue=12 |pages=1501–7 |year=2003 |pmid=12867584 |doi=10.1093/rheumatology/keg404 |url=}}</ref>
!HLA class2<ref name="pmid12867584">{{cite journal |vauthors=Lee HS, Chung YH, Kim TG, Kim TH, Jun JB, Jung S, Bae SC, Yoo DH |title=Independent association of HLA-DR and FCgamma receptor polymorphisms in Korean patients with systemic lupus erythematosus |journal=Rheumatology (Oxford) |volume=42 |issue=12 |pages=1501–7 |year=2003 |pmid=12867584 |doi=10.1093/rheumatology/keg404 |url=}}</ref>
| colspan="1" rowspan="1" |
| colspan="1" rowspan="1" |
* Contains [[genes]] encoding [[glycoproteins]] that process and present [[peptides]] for recognition by [[T cells]] (antigen presenting cells)
* Contains [[genes]] encoding [[glycoproteins]] that process and present [[peptides]] for recognition by [[T cells]] ([[Antigen-presenting cell|antigen presenting cells]])
* The most important related genes:
* The most important related [[Gene|genes]]:
** HLA-DR2
** [[HLA-DR2]]
** HLA-DR3  
** [[HLA-DR3]]
|
|
* Associated with an overall 2 to 3 fold increase in the risk of SLE  
* Associated with an overall 2 to 3 fold increase in the risk of SLE  
* More in European and Asian
* More in European and Asian
* HLA-DQ and HLA-DR alleles:
* [[HLA-DQ]] and [[HLA-DR]] alleles:
** Strong association with SLE autoantibodies
** Strong association with SLE [[autoantibodies]]
|-
|-
!HLA class3<ref name="pmid11079100">{{cite journal |vauthors=Pickering MC, Botto M, Taylor PR, Lachmann PJ, Walport MJ |title=Systemic lupus erythematosus, complement deficiency, and apoptosis |journal=Adv. Immunol. |volume=76 |issue= |pages=227–324 |year=2000 |pmid=11079100 |doi= |url=}}</ref>
!HLA class3<ref name="pmid11079100">{{cite journal |vauthors=Pickering MC, Botto M, Taylor PR, Lachmann PJ, Walport MJ |title=Systemic lupus erythematosus, complement deficiency, and apoptosis |journal=Adv. Immunol. |volume=76 |issue= |pages=227–324 |year=2000 |pmid=11079100 |doi= |url=}}</ref>
|
|
* Contains important immune genes including:
* Contains important [[Gene|immune genes]] including:
** C2 gene
** C2 [[gene]]
** C4 gene
** C4 [[gene]]
** Encode complement proteins
** Encode [[Complement|complement proteins]]
* The complement system act through opsonization:
* The [[complement system]] act through [[opsonization]]:
** Facilitates the clearance of apoptotic debris and cellular fragments
** Facilitates the clearance of [[Apoptosis|apoptotic debris]] and cellular fragments
** The fragments might contain nuclear antigens, which are targets for SLE-associated autoantibodies
** The fragments may contain nuclear antigens, which are targets for SLE-associated [[autoantibodies]]
* Complement C4-A has a higher affinity for immune complexes
* [[Complement]] C4-A has a higher affinity for [[immune complexes]]
* Circulating complement C4 proteins clear immune complexes
* Circulating [[complement]] C4 proteins clear [[Immune complex|immune complexes]]
|
|
* Complete C2 and C4 deficiencies:
* Complete C2 and C4 deficiencies:
** Rare
** Rare
** Associated with a mild form of SLE that affects mostly the joints and skin
** Associated with a mild form of SLE that affects mostly the [[joints]] and [[skin]]
* Stronger genetic evidence for an association with SLE in C4A than C4-B
* Stronger [[Genetics|genetic]] evidence for an association with SLE in C4A than C4-B
* Circulating complement C4 proteins deficiency will promote autoimmunity
* Circulating complement C4 proteins deficiency will promote [[autoimmunity]]
|-  
|-  
! rowspan="4" |Non-HLA   
! rowspan="4" |Non-HLA   
!Interferon (IFN) regulatory factor 5<ref name="pmid20080916">{{cite journal |vauthors=Löfgren SE, Yin H, Delgado-Vega AM, Sanchez E, Lewén S, Pons-Estel BA, Witte T, D'Alfonso S, Ortego-Centeno N, Martin J, Alarcón-Riquelme ME, Kozyrev SV |title=Promoter insertion/deletion in the IRF5 gene is highly associated with susceptibility to systemic lupus erythematosus in distinct populations, but exerts a modest effect on gene expression in peripheral blood mononuclear cells |journal=J. Rheumatol. |volume=37 |issue=3 |pages=574–8 |year=2010 |pmid=20080916 |doi=10.3899/jrheum.090440 |url=}}</ref>
![[IRF5|Interferon (IFN) regulatory factor 5]]<ref name="pmid20080916">{{cite journal |vauthors=Löfgren SE, Yin H, Delgado-Vega AM, Sanchez E, Lewén S, Pons-Estel BA, Witte T, D'Alfonso S, Ortego-Centeno N, Martin J, Alarcón-Riquelme ME, Kozyrev SV |title=Promoter insertion/deletion in the IRF5 gene is highly associated with susceptibility to systemic lupus erythematosus in distinct populations, but exerts a modest effect on gene expression in peripheral blood mononuclear cells |journal=J. Rheumatol. |volume=37 |issue=3 |pages=574–8 |year=2010 |pmid=20080916 |doi=10.3899/jrheum.090440 |url=}}</ref>
| colspan="1" rowspan="1" |
| colspan="1" rowspan="1" |
* Code a transcription factor in the type 1 interferon pathway
* Code a [[transcription factor]] in the type 1 [[interferon]] pathway
* Regulates:
* Regulates:
** Expression of IFN-dependent genes
** Expression of [[IFN]]-dependent [[genes]]
** Inflammatory cytokines
** [[Cytokine|Inflammatory cytokines]]
** Genes involved in apoptosis
** [[Genes]] involved in [[apoptosis]]
|
|
* The most strongly and consistently SLE-associated loci outside the MHC region
* The most strongly and consistently SLE-associated loci outside the [[MHC|MHC region]]


* Upon activation, IRF5 activates transcription of type I IFN and pro-inflammatory cytokines such as TNFα, IL-12 and IL-6
* Upon activation, [[IRF5]] activates transcription of [[Interferon type I|type I IFN]] and [[proinflammatory]] cytokines such as [[TNFα]], [[IL-12]] and [[IL-6]]


* Specific combinations of several polymorphisms in the ''IRF5'' region interact to increase disease risk
* Specific combinations of several [[polymorphisms]] in the [[IRF5]] region interact to increase disease risk
|-
|-
!STAT4<ref name="pmid18579578">{{cite journal |vauthors=Sigurdsson S, Nordmark G, Garnier S, Grundberg E, Kwan T, Nilsson O, Eloranta ML, Gunnarsson I, Svenungsson E, Sturfelt G, Bengtsson AA, Jönsen A, Truedsson L, Rantapää-Dahlqvist S, Eriksson C, Alm G, Göring HH, Pastinen T, Syvänen AC, Rönnblom L |title=A risk haplotype of STAT4 for systemic lupus erythematosus is over-expressed, correlates with anti-dsDNA and shows additive effects with two risk alleles of IRF5 |journal=Hum. Mol. Genet. |volume=17 |issue=18 |pages=2868–76 |year=2008 |pmid=18579578 |pmc=2525501 |doi=10.1093/hmg/ddn184 |url=}}</ref><ref name="pmid19109131">{{cite journal |vauthors=Kariuki SN, Kirou KA, MacDermott EJ, Barillas-Arias L, Crow MK, Niewold TB |title=Cutting edge: autoimmune disease risk variant of STAT4 confers increased sensitivity to IFN-alpha in lupus patients in vivo |journal=J. Immunol. |volume=182 |issue=1 |pages=34–8 |year=2009 |pmid=19109131 |pmc=2716754 |doi= |url=}}</ref><ref name="pmid18516230">{{cite journal |vauthors=Taylor KE, Remmers EF, Lee AT, Ortmann WA, Plenge RM, Tian C, Chung SA, Nititham J, Hom G, Kao AH, Demirci FY, Kamboh MI, Petri M, Manzi S, Kastner DL, Seldin MF, Gregersen PK, Behrens TW, Criswell LA |title=Specificity of the STAT4 genetic association for severe disease manifestations of systemic lupus erythematosus |journal=PLoS Genet. |volume=4 |issue=5 |pages=e1000084 |year=2008 |pmid=18516230 |pmc=2377340 |doi=10.1371/journal.pgen.1000084 |url=}}</ref><ref name="pmid18803832">{{cite journal |vauthors=Kawasaki A, Ito I, Hikami K, Ohashi J, Hayashi T, Goto D, Matsumoto I, Ito S, Tsutsumi A, Koga M, Arinami T, Graham RR, Hom G, Takasaki Y, Hashimoto H, Behrens TW, Sumida T, Tsuchiya N |title=Role of STAT4 polymorphisms in systemic lupus erythematosus in a Japanese population: a case-control association study of the STAT1-STAT4 region |journal=Arthritis Res. Ther. |volume=10 |issue=5 |pages=R113 |year=2008 |pmid=18803832 |pmc=2592800 |doi=10.1186/ar2516 |url=}}</ref>
!STAT4<ref name="pmid18579578">{{cite journal |vauthors=Sigurdsson S, Nordmark G, Garnier S, Grundberg E, Kwan T, Nilsson O, Eloranta ML, Gunnarsson I, Svenungsson E, Sturfelt G, Bengtsson AA, Jönsen A, Truedsson L, Rantapää-Dahlqvist S, Eriksson C, Alm G, Göring HH, Pastinen T, Syvänen AC, Rönnblom L |title=A risk haplotype of STAT4 for systemic lupus erythematosus is over-expressed, correlates with anti-dsDNA and shows additive effects with two risk alleles of IRF5 |journal=Hum. Mol. Genet. |volume=17 |issue=18 |pages=2868–76 |year=2008 |pmid=18579578 |pmc=2525501 |doi=10.1093/hmg/ddn184 |url=}}</ref><ref name="pmid19109131">{{cite journal |vauthors=Kariuki SN, Kirou KA, MacDermott EJ, Barillas-Arias L, Crow MK, Niewold TB |title=Cutting edge: autoimmune disease risk variant of STAT4 confers increased sensitivity to IFN-alpha in lupus patients in vivo |journal=J. Immunol. |volume=182 |issue=1 |pages=34–8 |year=2009 |pmid=19109131 |pmc=2716754 |doi= |url=}}</ref><ref name="pmid18516230">{{cite journal |vauthors=Taylor KE, Remmers EF, Lee AT, Ortmann WA, Plenge RM, Tian C, Chung SA, Nititham J, Hom G, Kao AH, Demirci FY, Kamboh MI, Petri M, Manzi S, Kastner DL, Seldin MF, Gregersen PK, Behrens TW, Criswell LA |title=Specificity of the STAT4 genetic association for severe disease manifestations of systemic lupus erythematosus |journal=PLoS Genet. |volume=4 |issue=5 |pages=e1000084 |year=2008 |pmid=18516230 |pmc=2377340 |doi=10.1371/journal.pgen.1000084 |url=}}</ref><ref name="pmid18803832">{{cite journal |vauthors=Kawasaki A, Ito I, Hikami K, Ohashi J, Hayashi T, Goto D, Matsumoto I, Ito S, Tsutsumi A, Koga M, Arinami T, Graham RR, Hom G, Takasaki Y, Hashimoto H, Behrens TW, Sumida T, Tsuchiya N |title=Role of STAT4 polymorphisms in systemic lupus erythematosus in a Japanese population: a case-control association study of the STAT1-STAT4 region |journal=Arthritis Res. Ther. |volume=10 |issue=5 |pages=R113 |year=2008 |pmid=18803832 |pmc=2592800 |doi=10.1186/ar2516 |url=}}</ref>
Line 167: Line 167:
* Encodes the signal transducer and activator of transcription 4 protein
* Encodes the signal transducer and activator of transcription 4 protein
|
|
* associated with a more- severe SLE phenotype:
* Associated with a more severe SLE [[phenotype]]:
** Disease-onset at a young age (<30 years)
** Disease-onset at a young age (<30 years)
** High frequency of nephritis
** High frequency of [[nephritis]]
* The presence of antibodies towards double-stranded DNA
* Associated with the presence of [[antibodies]] towards [[Double-stranded DNA helix|double-stranded DNA]]
* An increased sensitivity to IFN-α signaling in peripheral blood mononuclear cells
* [[Mutation]] lead to an increased [[sensitivity]] to [[Interferon-alpha|IFN-α]] signaling in peripheral blood [[mononuclear cells]]
|-
|-
!PTPN22<ref name="pmid19302045">{{cite journal |vauthors=Gregersen PK, Olsson LM |title=Recent advances in the genetics of autoimmune disease |journal=Annu. Rev. Immunol. |volume=27 |issue= |pages=363–91 |year=2009 |pmid=19302045 |pmc=2992886 |doi=10.1146/annurev.immunol.021908.132653 |url=}}</ref>
!PTPN22<ref name="pmid19302045">{{cite journal |vauthors=Gregersen PK, Olsson LM |title=Recent advances in the genetics of autoimmune disease |journal=Annu. Rev. Immunol. |volume=27 |issue= |pages=363–91 |year=2009 |pmid=19302045 |pmc=2992886 |doi=10.1146/annurev.immunol.021908.132653 |url=}}</ref>
|
|
* Encodes a lymphoid-specific phosphatase that inhibits T-cell activation
* Encodes a [[lymphoid]]-specific [[Phosphatases|phosphatase]] that inhibits [[T cell|T-cell]] activation
|
|
* Associated with a higher risk of developing multiple autoimmune diseases
* Associated with a higher risk of developing [[Autoimmune disease|multiple autoimmune diseases]]
* In European populations
* More seen in European populations
* Increases the intrinsic lymphoid-specific phosphatase activity that lead to:
* [[Mutation]] increases the intrinsic [[lymphoid]]-specific [[Phosphatases|phosphatase]] activity that lead to:
** Reduced T-cell receptor (TCR) signaling threshold
** Reduced [[T cell receptor|T-cell receptor (TCR)]] signaling threshold
** Promotes autoimmunity
** Promotes [[autoimmunity]]
|-
|-
!FcγR genes<ref name="pmid10413210">{{cite journal |vauthors=Yap SN, Phipps ME, Manivasagar M, Tan SY, Bosco JJ |title=Human Fc gamma receptor IIA (FcgammaRIIA) genotyping and association with systemic lupus erythematosus (SLE) in Chinese and Malays in Malaysia |journal=Lupus |volume=8 |issue=4 |pages=305–10 |year=1999 |pmid=10413210 |doi=10.1191/096120399678847876 |url=}}</ref>
!FcγR genes<ref name="pmid10413210">{{cite journal |vauthors=Yap SN, Phipps ME, Manivasagar M, Tan SY, Bosco JJ |title=Human Fc gamma receptor IIA (FcgammaRIIA) genotyping and association with systemic lupus erythematosus (SLE) in Chinese and Malays in Malaysia |journal=Lupus |volume=8 |issue=4 |pages=305–10 |year=1999 |pmid=10413210 |doi=10.1191/096120399678847876 |url=}}</ref>
|
|
* Encode proteins that :
* Encode [[proteins]] that :
** Recognize immune complexes
** Recognize [[immune complexes]]
** Involved in antibody-dependent responses
** Involved in [[Antibody-dependent cellular cytotoxicity|antibody-dependent]] responses
|
|
* Mutation associated with:
* [[Mutation]] associated with:
** Low affinity for IgG2-opsonized particles
** Low affinity for [[Immunoglobulin G|IgG2-opsonized]] particles
** Reduced clearance of ICs
** Reduced clearance of [[immune complexes]]
|-  
|-  
! rowspan="5" |
! rowspan="5" |
!C1q genes<ref name="pmid11079100">{{cite journal |vauthors=Pickering MC, Botto M, Taylor PR, Lachmann PJ, Walport MJ |title=Systemic lupus erythematosus, complement deficiency, and apoptosis |journal=Adv. Immunol. |volume=76 |issue= |pages=227–324 |year=2000 |pmid=11079100 |doi= |url=}}</ref>
!C1q genes<ref name="pmid11079100">{{cite journal |vauthors=Pickering MC, Botto M, Taylor PR, Lachmann PJ, Walport MJ |title=Systemic lupus erythematosus, complement deficiency, and apoptosis |journal=Adv. Immunol. |volume=76 |issue= |pages=227–324 |year=2000 |pmid=11079100 |doi= |url=}}</ref>
| colspan="1" rowspan="1" |
| colspan="1" rowspan="1" |
* Encode complement proteins:
* The [[complement system]] act through [[opsonization]]:
** Through opsonization, facilitates the clearance of apoptotic debris and cellular fragments
** Facilitates the clearance of [[Apoptosis|apoptotic debris]] and cellular fragments
** These fragments might contain nuclear antigens, which are targets for SLE-associated autoantibodies.
** The fragments may contain nuclear antigens, which are targets for SLE-associated [[autoantibodies]]
|
|
Homozygous deficiency of ''C1q:''
* [[Homozygous]] deficiency of ''C1q''
* Very rare disease
** Rare
* Develop a severe and early onset form of SLE
** Develop a severe and early onset form of SLE
* Associated with severe glomerulonephritis and skin manifestations
** Associated with severe [[glomerulonephritis]] and [[skin]] manifestations
|-
|-
!The ''IRAK1-MECP2'' region
!The ''IRAK1-MECP2'' region
|
|
* Encode a protein kinase:
* Encode a [[protein kinase]]:
** Regulates multiple pathways in both innate and adaptive immune responses by linking several immune-receptor-complexes to TNF receptor-associated factor 6
** Regulates multiple pathways in both [[Innate immune system|innate]] and [[Adaptive immune response|adaptive immune responses]] by linking several immune-receptor-complexes to [[TNF]] receptor-associated factor 6
** Critical role in the transcriptional suppression of methylation-sensitive genes
** Critical role in the [[Transcriptional regulation|transcriptional suppression]] of [[methylation]]-sensitive genes
|
|
|-
|-
!TREX1
!TREX1
|
|
* Encodes a major exonuclease:
* Encodes a major [[exonuclease]]:
** Proofreads DNA polymerase
** Proofreads [[DNA polymerase]]
** Functions also as a DNA-degrading enzyme in granzyme-A-mediated apoptosis
** Functions also as a [[DNA]]-degrading enzyme in [[granzyme]]-A-mediated apoptosis
** Act as a cytosolic DNA sensor
** Act as a [[cytosolic]] [[DNA]] sensor
|
|
* Impairs DNA damage repair lead to the following consequences:
* Mutation lead to impairs [[DNA damage]] repair, that lead to:
*# Accumulation of endogenous retroelement-derived DNA
*# Accumulation of [[endogenous]] retroelement-derived [[DNA]]
*# Defective clearance of this DNA induces IFN production
*# Defective clearance of this [[DNA]] induces [[IFN-α|IFN]] production
*# An immune-mediated inflammatory response
*# An [[Immune-mediated disease|immune-mediated inflammatory response]]
*# Systemic autoimmunity
*# Systemic [[autoimmunity]]
|-
|-
!TNFSF4
!TNFSF4
|
|
* The genes in this loci produce interaction induces the production of co-stimulatory signals to activate T cells.
* The [[genes]] in this loci produce interaction induces the production of co-stimulatory signals to activate [[T cells]]
|
|
* Inhibits the generation and function of IL-10-producing CD4+type 1 regulatory T cells
* Inhibits the generation and function of [[IL-10]] producing CD4+ [[T cells]]
* Induces B-cell activation and differentiation
* Induces [[B-cell]] activation and differentiation
* Induces IL-17 production
* Induces [[IL17A|IL-17]] production
* Predispose to SLE:
* [[Mutation]] lead to predisposition to SLE:
** Augmenting the interaction between T cells and antigen-presenting cells
** Augmenting the interaction between [[T cells]] and [[antigen-presenting cells]]
** Influencing the functional consequences of T-cell activation
** Influencing the functional consequences of [[T cell|T-cell activation]]
|-
|-
!IL-10
!IL-10
|
|
* Encodes IL-10
* Encodes [[IL-10]]
* An important regulatory cytokine with both immunosuppressive and immunostimulatory properties
* An important [[Cytokine|regulatory cytokine]] with both [[immunosuppressive]] and [[Immunostimulator|immunostimulatory]] properties
|
|
* Increased IL-10 production by B cells and monocytes from patients with SLE is known to correlate with disease activity
* Increased [[IL-10]] production by [[B cells]] and [[monocytes]] from patients with SLE is known to correlate with disease activity
|-
|-
! rowspan="2" |Regulators of IFNα
! rowspan="2" |Regulators of IFNα
!TNFAIP3 and TNIP1
!TNFAIP3 and TNIP1
|
|
* Key regulators of the NFκB signaling pathway
* Encodes key regulators of the [[NFκB]] signaling pathway
* Modulate cell activation, cytokine signaling and apoptosis
* Modulate cell activation, [[cytokine]] signaling and [[apoptosis]]
|
|
* The exact pathogenetics is not completely known
* The exact [[Pathogenicity|pathogenetics]] is not completely known
|-
|-
!PHRF1
!PHRF1
|
|
* Encodes an elongation factor
* Encodes an [[elongation factor]]
|
|
* Related to SLE-associated autoantibodies and elevated IFN-α activity
* Related to SLE-associated [[Autoantibody|autoantibodies]] and elevated [[IFN-α]] activity
|-
|-
! rowspan="5" |Regulators of Lymphocytes
! rowspan="5" |Regulators of Lymphocytes
!BLK<ref name="pmid19180478">{{cite journal |vauthors=Ito I, Kawasaki A, Ito S, Hayashi T, Goto D, Matsumoto I, Tsutsumi A, Hom G, Graham RR, Takasaki Y, Hashimoto H, Ohashi J, Behrens TW, Sumida T, Tsuchiya N |title=Replication of the association between the C8orf13-BLK region and systemic lupus erythematosus in a Japanese population |journal=Arthritis Rheum. |volume=60 |issue=2 |pages=553–8 |year=2009 |pmid=19180478 |doi=10.1002/art.24246 |url=}}</ref>
!BLK<ref name="pmid19180478">{{cite journal |vauthors=Ito I, Kawasaki A, Ito S, Hayashi T, Goto D, Matsumoto I, Tsutsumi A, Hom G, Graham RR, Takasaki Y, Hashimoto H, Ohashi J, Behrens TW, Sumida T, Tsuchiya N |title=Replication of the association between the C8orf13-BLK region and systemic lupus erythematosus in a Japanese population |journal=Arthritis Rheum. |volume=60 |issue=2 |pages=553–8 |year=2009 |pmid=19180478 |doi=10.1002/art.24246 |url=}}</ref>
|
|
* encodes a protein kinase:
* Encodes a [[protein kinase]]:
** Mediates intra-cellular signaling
** Mediates [[intracellular signaling]]
** Influences B cells proliferation and differentiation
** Influences [[B cells]] proliferation and differentiation
** Influence tolerance of B cells
** Influence tolerance of [[B cells]]
|
|
* More common in Chinese and Japanese populations
* More common in Chinese and Japanese populations
|-
|-
!''BANK1''
!''BANK1''
: 11782428
:: 18204447
|
|
* A B-cell adaptor protein
* Encodes a [[B cell|B-cell]] adaptor protein
* Regulates direct coupling between a family of tyrosine kinases and the calcium channel IP3R
* Facilitates the release of [[intracellular]] [[calcium]]
* Facilitates the release of intracellular calcium
* Alter the [[B-cell]] activation threshold
* Alter the B-cell activation threshold
| rowspan="2" |
| rowspan="2" |
* Lead to hyperctivation of B-cell receptors and the subsequent B-cell hyperactivity that is commonly observed in SLE
* Mutations lead to hyperctivation of [[B-cell receptor|B-cell receptors]] and the subsequent [[B-cell]] hyperactivity that is commonly observed in SLE
|-
|-
!LYN
!LYN
: 18204446
|
|
* Mediates B-cell activation
* Mediates [[B-cell]] activation
* Mediates B-cell inhibition
* Mediates [[B-cell]] inhibition
|-
|-
!''ETS1'' 
!''ETS1''
17967903
 
19838195 
|
|
* Negatively regulates the differentiation of B cells and type 17 T-helper cells
* Negatively regulates the differentiation of [[B cells]] and type 17 [[T-helper cells]]
* Regulates lymphocytes by inhibiting the function of an important transcription factor in plasma cells
* Regulates [[Lymphocyte|lymphocytes]] by inhibiting the function of an important [[transcription factor]] in [[Plasma cell|plasma cells]]
|
|
|-
|-
!IKZF1
!IKZF1
:
: 17357110
|
|
* Lymphoid-restricted transcription factor
* Encode a [[lymphoid]]-restricted [[transcription factor]]
* Regulates:
* Regulates:
** Lymphocyte differentiation and proliferation
** [[Lymphocyte]] differentiation and proliferation
** Self-tolerance through regulation of B-cell-receptor signaling
** Self-tolerance through regulation of B-cell-receptor signaling
|
|
Line 300: Line 308:
!Genes involved in immune complex clearance
!Genes involved in immune complex clearance
!''ITGAM''
!''ITGAM''
19838195
|
|
* The encoded protein binds the complement cleavage fragment of C3b
* Encode a [[protein]] that binds the [[complement]] cleavage fragment of [[C3b]]
|
|
* Contributed to SLE susceptibility
* Contributed to SLE susceptibility

Revision as of 14:32, 28 July 2017

https://https://www.youtube.com/watch?v=0junqD4BLH4&wmode=transparent%7C350}}

Systemic lupus erythematosus Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Systemic lupus erythematosus from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Lupus and Quality of Life

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Systemic lupus erythematosus pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Systemic lupus erythematosus pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

National Guidelines Clearinghouse

NICE Guidance

FDA on Systemic lupus erythematosus pathophysiology

on Systemic lupus erythematosus pathophysiology

Systemic lupus erythematosus pathophysiology in the news

Blogs onSystemic lupus erythematosus pathophysiology

Directions to Hospitals Treating Systemic lupus erythematosus

Risk calculators and risk factors for Systemic lupus erythematosus pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mahshid Mir, M.D. [2] Cafer Zorkun, M.D., Ph.D. [3] Raviteja Guddeti, M.B.B.S. [4]

Overview

The pathophysiology of systemic lupus erythematosus involves the immune system. There are other factors like genetic factors, hormonal abnormalities, and environmental factors that play some roles as well. The most prominent events involving immune abnormalities are related to persistent activation of B cells and plasma cells that make auto-antibodies during disease progression. The most prominent events involving hormonal abnormalities are due to prolactin and estrogen. The most important environmental factors related to disease progression are ultraviolet (UV) light and some infections. On microscopic histopathological analysis, apoptotic keratinocytes, vacuolization of the basement membrane, and dermal mucin deposition are characteristic findings of SLE dermatitis, and active or inactive endocapillary or extracapillary segmental glomerulonephritis are characteristic findings of SLE nephritis.

Pathogenesis

The progression of systemic lupus erythematosus (SLE) involves the immune system. Nearly all of the pathological manifestation of SLE are due to antibody formation and the creation and deposition of immune complexes in different organs of the body. When the immune complexes are formed, they will deposit in different body tissues and vessels, which may lead to complement activation and more organ damage. There are other factors like genetic factors, hormonal abnormalities, and environmental factors that play some roles as well.

Immune abnormalities

Development of systemic lupus erythematosus (SLE) is the due to activation of different mechanisms that may result in auto-immunity. As a result, body tissues lose their self-tolerance. Affected patients are no longer entirely tolerant to all of their self-antigens, consequently progress to an autoimmune disease and develop auto antibodies as a response. During disease progression, B cells and plasma cells that make autoantibodies are more persistently activated and thus make more autoantibodies. These autoantibodies are targeted predominantly to intracellular nucleoprotein particles.[1][2] This increase in autoantibody production and persistence is supposed to be downregulated by anti-idiotypic antibodies or regulatory immune cells, but the massive immunologic response in SLE prevents this downregulation to take place. The most important immune abnormalities that are related to SLE development and progression are: 

Signaling abnormalities

  • Protein kinases are responsible for intracellular cytokine signal. Intracellular signaling is leading to various types of cell response, such as:
    • Cell migration
    • Cell proliferation
    • Inflammatory response
  • Cell signaling abnormalities will lead to:
    • T and B lymphocytes cellular hyperactivity
    • T and B lymphocytes hyper responsiveness
    • Persistence of autoreactive T cells that would otherwise have been deleted
  • Signaling abnormalities of T and B lymphocytes, may be due to:

General

  • Increased expression of specific genetic factors that may be associated with promoting autoimmunity
  • Increased expression of interferon alpha (IFN-α) inducible RNA transcripts by mononuclear cells leads to elevated levels of IFN-α.[3] Increased availability of stimulatory nucleic acids would implicate IFN-I production, that is responsible for chronic and recurrent characteristics of the SLE.
  • Elevated levels of circulating TNF-alpha correlate with active disease, and TNF is expressed in renal tissue in lupus nephritis
  • Abnormally high levels of CD4 on erythrocytes (E-CD4) and low levels of erythrocyte complement receptor type one (E-CR1) are characteristic of SLE, and combined measurement of the 2 molecules has high diagnostic sensitivity and specificity for lupus

Neutrophil

Microparticles

B-Cell related

T-Cell related

Hormonal abnormalities

The following evidence is suggestive of the hormonal predisposition to SLE:

Hormones that are related to disease progression:[7]

Environmental factors


Lupus nephritis

In the initial phase of the disease, the immune deposits and/or autoantibodies induce cytokine production in renal resident cells, leading to further inflammatory cytokine/chemokine expression and leukocyte infiltration and activation. Then, infiltrate leukocytes, such as macrophages (Mφ) and dendritic cells (DCs), secrete a variety of cytokines and activate naïve T cells, leading the cytokine profile towards T helper (Th)1, Th2, and/or Th17.

The current paradigm is that LN results from immune complex deposition in the renal glomeruli leading to complement activation, chronic inflammation and renal insufficiency defined by histopathology and the presence of proteinuria and cellular casts.

Genetics

Systemic lupus erythematosus is transmitted in polygenic inheritance pattern. Genes involved in the pathogenesis of systemic lupus erythematosus include HLA class 2 especially DR2 nd DR3, HLA class 3 especially complement genes include C2 and C4 genes, IFNRF5 gene, and other genes related to immunologic system as well.

The following evidence is also suggestive of the genetic predisposition of SLE:[10]

  • Increase of disease occurrence in identical twins
  • Increased disease frequency among first degree relatives
  • The increased risk of developing the disease in siblings of SLE patients
Classification Gene subtype Function Pathological effect and Molecular mechanisms
HLA HLA class2[11]
  • Associated with an overall 2 to 3 fold increase in the risk of SLE
  • More in European and Asian
  • HLA-DQ and HLA-DR alleles:
HLA class3[12]
  • Complete C2 and C4 deficiencies:
    • Rare
    • Associated with a mild form of SLE that affects mostly the joints and skin
  • Stronger genetic evidence for an association with SLE in C4A than C4-B
  • Circulating complement C4 proteins deficiency will promote autoimmunity
Non-HLA Interferon (IFN) regulatory factor 5[13]
  • The most strongly and consistently SLE-associated loci outside the MHC region
  • Specific combinations of several polymorphisms in the IRF5 region interact to increase disease risk
STAT4[14][15][16][17]
  • Encodes the signal transducer and activator of transcription 4 protein
PTPN22[18]
FcγR genes[19]
C1q genes[12]
The IRAK1-MECP2 region
TREX1
TNFSF4
  • The genes in this loci produce interaction induces the production of co-stimulatory signals to activate T cells
IL-10
  • Increased IL-10 production by B cells and monocytes from patients with SLE is known to correlate with disease activity
Regulators of IFNα TNFAIP3 and TNIP1
  • Encodes key regulators of the NFκB signaling pathway
  • Modulate cell activation, cytokine signaling and apoptosis
PHRF1
Regulators of Lymphocytes BLK[20]
  • More common in Chinese and Japanese populations
BANK1
11782428
18204447
  • Mutations lead to hyperctivation of B-cell receptors and the subsequent B-cell hyperactivity that is commonly observed in SLE
LYN
18204446
ETS1

17967903

19838195 

IKZF1
17357110
  • A novel SLE susceptibility locus in a Chinese population
  • A strong candidate locus in European-derived populations
Genes involved in immune complex clearance ITGAM

19838195

  • Contributed to SLE susceptibility

Associated Conditions

Gross Pathology

On gross pathology of kidney, bilateral pallor, and hypertrophy of kidneys are characteristic findings of systemic lupus erythematosus.

On gross pathology of brain, infarct regions and hemorrhages are characteristic findings of systemic lupus erythematosus.

On gross pathology of cardiac valves, cardiomegaly and valvular vegetation are characteristic findings of systemic lupus erythematosus.

On gross pathology of pleura, pleuritis and pleural fibrosis are characteristic findings of systemic lupus erythematosus.

Microscopic Pathology

On microscopic histopathological analysis, apoptotic keratinocytes, vacuolization of the basement membrane, and dermal mucin deposition are characteristic findings of SLE dermatitis, and active or inactive endocapillary or extracapillary segmental glomerulonephritis are characteristic findings of SLE nephritis.

Skin involvement histopathology:

Common shared histopathologic features among all different subtypes of cutaneous lupus include:

SLE dermatitis subtype Specific microscopic findings
Acute cutaneous lupus erythematosus
Subacute cutaneous lupus erythematosus
Chronic cutaneous lupus erythematosus

Glomerulonephritis histopathology:

Class SLE nephritis subtype Light microscopy findings Electron microscopy/Immunofluorescence findings
I Minimal mesangial lupus nephritis -
II Mesangial proliferative lupus nephritis
III Focal lupus nephritis
IV Diffuse lupus nephritis
  • Subendothelial deposits specially during the active phase
  • Diffuse wire loop deposits with little or no glomerular proliferation
V Lupus membranous nephropathy
VI Advanced sclerosing lupus nephritis

Synovial involvement histopathology

Mucosal involvement histopathology


Videos

{{#ev:youtube|Tw07BFaDEo0}}

References

  1. Elkon K (1995). "Autoantibodies in systemic lupus erythematosus". Curr Opin Rheumatol. 7 (5): 384–8. PMID 8519610.
  2. Yaniv G, Twig G, Shor DB, Furer A, Sherer Y, Mozes O, Komisar O, Slonimsky E, Klang E, Lotan E, Welt M, Marai I, Shina A, Amital H, Shoenfeld Y (2015). "A volcanic explosion of autoantibodies in systemic lupus erythematosus: a diversity of 180 different antibodies found in SLE patients". Autoimmun Rev. 14 (1): 75–9. doi:10.1016/j.autrev.2014.10.003. PMID 25449682.
  3. Kirou KA, Lee C, George S, Louca K, Papagiannis IG, Peterson MG, Ly N, Woodward RN, Fry KE, Lau AY, Prentice JG, Wohlgemuth JG, Crow MK (2004). "Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus". Arthritis Rheum. 50 (12): 3958–67. doi:10.1002/art.20798. PMID 15593221.
  4. Barnado A, Crofford LJ, Oates JC (2016). "At the Bedside: Neutrophil extracellular traps (NETs) as targets for biomarkers and therapies in autoimmune diseases". J. Leukoc. Biol. 99 (2): 265–78. doi:10.1189/jlb.5BT0615-234R. PMID 26658004.
  5. Dye JR, Ullal AJ, Pisetsky DS (2013). "The role of microparticles in the pathogenesis of rheumatoid arthritis and systemic lupus erythematosus". Scand. J. Immunol. 78 (2): 140–8. doi:10.1111/sji.12068. PMID 23672591.
  6. Costenbader KH, Feskanich D, Stampfer MJ, Karlson EW (2007). "Reproductive and menopausal factors and risk of systemic lupus erythematosus in women". Arthritis Rheum. 56 (4): 1251–62. doi:10.1002/art.22510. PMID 17393454.
  7. 7.0 7.1 Lahita RG (1999). "The role of sex hormones in systemic lupus erythematosus". Curr Opin Rheumatol. 11 (5): 352–6. PMID 10503654.
  8. Hughes GC, Choubey D (2014). "Modulation of autoimmune rheumatic diseases by oestrogen and progesterone". Nat Rev Rheumatol. 10 (12): 740–51. doi:10.1038/nrrheum.2014.144. PMID 25155581.
  9. Cohen-Solal JF, Jeganathan V, Grimaldi CM, Peeva E, Diamond B (2006). "Sex hormones and SLE: influencing the fate of autoreactive B cells". Curr. Top. Microbiol. Immunol. 305: 67–88. PMID 16724801.
  10. Sullivan KE (2000). "Genetics of systemic lupus erythematosus. Clinical implications". Rheum. Dis. Clin. North Am. 26 (2): 229–56, v–vi. PMID 10768211.
  11. Lee HS, Chung YH, Kim TG, Kim TH, Jun JB, Jung S, Bae SC, Yoo DH (2003). "Independent association of HLA-DR and FCgamma receptor polymorphisms in Korean patients with systemic lupus erythematosus". Rheumatology (Oxford). 42 (12): 1501–7. doi:10.1093/rheumatology/keg404. PMID 12867584.
  12. 12.0 12.1 Pickering MC, Botto M, Taylor PR, Lachmann PJ, Walport MJ (2000). "Systemic lupus erythematosus, complement deficiency, and apoptosis". Adv. Immunol. 76: 227–324. PMID 11079100.
  13. Löfgren SE, Yin H, Delgado-Vega AM, Sanchez E, Lewén S, Pons-Estel BA, Witte T, D'Alfonso S, Ortego-Centeno N, Martin J, Alarcón-Riquelme ME, Kozyrev SV (2010). "Promoter insertion/deletion in the IRF5 gene is highly associated with susceptibility to systemic lupus erythematosus in distinct populations, but exerts a modest effect on gene expression in peripheral blood mononuclear cells". J. Rheumatol. 37 (3): 574–8. doi:10.3899/jrheum.090440. PMID 20080916.
  14. Sigurdsson S, Nordmark G, Garnier S, Grundberg E, Kwan T, Nilsson O, Eloranta ML, Gunnarsson I, Svenungsson E, Sturfelt G, Bengtsson AA, Jönsen A, Truedsson L, Rantapää-Dahlqvist S, Eriksson C, Alm G, Göring HH, Pastinen T, Syvänen AC, Rönnblom L (2008). "A risk haplotype of STAT4 for systemic lupus erythematosus is over-expressed, correlates with anti-dsDNA and shows additive effects with two risk alleles of IRF5". Hum. Mol. Genet. 17 (18): 2868–76. doi:10.1093/hmg/ddn184. PMC 2525501. PMID 18579578.
  15. Kariuki SN, Kirou KA, MacDermott EJ, Barillas-Arias L, Crow MK, Niewold TB (2009). "Cutting edge: autoimmune disease risk variant of STAT4 confers increased sensitivity to IFN-alpha in lupus patients in vivo". J. Immunol. 182 (1): 34–8. PMC 2716754. PMID 19109131.
  16. Taylor KE, Remmers EF, Lee AT, Ortmann WA, Plenge RM, Tian C, Chung SA, Nititham J, Hom G, Kao AH, Demirci FY, Kamboh MI, Petri M, Manzi S, Kastner DL, Seldin MF, Gregersen PK, Behrens TW, Criswell LA (2008). "Specificity of the STAT4 genetic association for severe disease manifestations of systemic lupus erythematosus". PLoS Genet. 4 (5): e1000084. doi:10.1371/journal.pgen.1000084. PMC 2377340. PMID 18516230.
  17. Kawasaki A, Ito I, Hikami K, Ohashi J, Hayashi T, Goto D, Matsumoto I, Ito S, Tsutsumi A, Koga M, Arinami T, Graham RR, Hom G, Takasaki Y, Hashimoto H, Behrens TW, Sumida T, Tsuchiya N (2008). "Role of STAT4 polymorphisms in systemic lupus erythematosus in a Japanese population: a case-control association study of the STAT1-STAT4 region". Arthritis Res. Ther. 10 (5): R113. doi:10.1186/ar2516. PMC 2592800. PMID 18803832.
  18. Gregersen PK, Olsson LM (2009). "Recent advances in the genetics of autoimmune disease". Annu. Rev. Immunol. 27: 363–91. doi:10.1146/annurev.immunol.021908.132653. PMC 2992886. PMID 19302045.
  19. Yap SN, Phipps ME, Manivasagar M, Tan SY, Bosco JJ (1999). "Human Fc gamma receptor IIA (FcgammaRIIA) genotyping and association with systemic lupus erythematosus (SLE) in Chinese and Malays in Malaysia". Lupus. 8 (4): 305–10. doi:10.1191/096120399678847876. PMID 10413210.
  20. Ito I, Kawasaki A, Ito S, Hayashi T, Goto D, Matsumoto I, Tsutsumi A, Hom G, Graham RR, Takasaki Y, Hashimoto H, Ohashi J, Behrens TW, Sumida T, Tsuchiya N (2009). "Replication of the association between the C8orf13-BLK region and systemic lupus erythematosus in a Japanese population". Arthritis Rheum. 60 (2): 553–8. doi:10.1002/art.24246. PMID 19180478.
  21. Petry F, Botto M, Holtappels R, Walport MJ, Loos M (2001). "Reconstitution of the complement function in C1q-deficient (C1qa-/-) mice with wild-type bone marrow cells". J. Immunol. 167 (7): 4033–7. PMID 11564823.
  22. Li R, Peng H, Chen GM, Feng CC, Zhang YJ, Wen PF, Qiu LJ, Leng RX, Pan HF, Ye DQ (2014). "Association of FCGR2A-R/H131 polymorphism with susceptibility to systemic lupus erythematosus among Asian population: a meta-analysis of 20 studies". Arch. Dermatol. Res. 306 (9): 781–91. doi:10.1007/s00403-014-1483-5. PMID 24997134.
  23. Sepehr A, Wenson S, Tahan SR (2010). "Histopathologic manifestations of systemic diseases: the example of cutaneous lupus erythematosus". J. Cutan. Pathol. 37 Suppl 1: 112–24. doi:10.1111/j.1600-0560.2010.01510.x. PMID 20482683.

Template:WH Template:WS